- Tytuł:
- Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.
- Autorzy:
- Źródło:
- Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2018 Apr; Vol. 47 (8), pp. 1117-1125. Date of Electronic Publication: 2018 Feb 15.
- Typ publikacji:
- Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
- MeSH Terms:
-
Adalimumab /*administration & dosage
Antibodies, Monoclonal, Humanized/*administration & dosage
Gastrointestinal Agents/*administration & dosage
Inflammatory Bowel Diseases/*drug therapy
Infliximab/*administration & dosage
Tumor Necrosis Factor-alpha/*antagonists & inhibitorsAdalimumab /adverse effects ;Adalimumab /pharmacokinetics ; Adult ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/pharmacokinetics ; Case-Control Studies ; Female ; Gastrointestinal Agents/adverse effects ; Gastrointestinal Agents/pharmacokinetics ; Humans ; Inflammatory Bowel Diseases/metabolism ; Infliximab/adverse effects ; Infliximab/pharmacokinetics ; Male ; Middle Aged
Czasopismo naukowe